cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.21954/ou.rd.5531911
title: Digital Brain Switch project - research data

description: <br>Digital Brain Switch (DBS; May 2013 – August 2015) was a project funded by the Engineering and Physical Sciences Research Council (EPSRC), which brought together computer science and social science. It was a collaboration between Lancaster University; The Open University; Royal Holloway, University of London; and University of Kent.<br>Data originates from a two year project examining the implications of digital technologies for work-life boundary management. Sample were 15 university students, 15 social entrepreneurs and 15 office workers across a range of institutions, organisations and contexts. Participants were recruited from a targeted invitation and all participated on a voluntary basis. Data consist of 45 week long video diaries consisting of instances of role transitions, textual transcription of simultaneous commentary and textual transcription of debriefing sessions. Additionally 45 hour long interview recordings and textual transcripts of further discussions of work-life issues, specifically work-life boundaries, work-life transitions and the effects of keeping video diaries. <br><br>Data were collected through hand held video cameras and recorded semi-structured interviews<br>Dataset contains sensitive personal information - restricted to project team only<br>This dataset contains the project's research data, in the following zip files:<br>1. 'Debriefs from video study.zip' - Notes taken during debriefs after participants completed the video study, exploring how they got on and what they learnt during the study2. 'Main study video data_Office workers.zip', 'Main study video data_Social Entrepreneurs.zip', 'Main study video data_Students.zip' - Video diary data3. 'Nvivo database of video data.zip' - Nvivo database of coded video diaries4. 'Office Worker Transcribed Interviews.zip', 'SE Transcribed Interviews', 'Student Transcribed Interviews.zip' - Transcriptions of audio recorded narrative interviews5. 'Transcripts_Office workers.zip', 'Transcripts_Social Entrepreneurs.zip', 'Transcripts_Students.zip' - Transcriptions of selected parts of video diaries6. 'READ_ME_DigitalBrainSwitch_ResearchData.txt' - a text file containing this description.<br>Supporting data is also archived on figshare at: 10.21954/ou.rd.5554840Pilot study data is also archived on figshare at: 10.21954/ou.rd.5549818<br>Data record in Open Research Online: http://oro.open.ac.uk/46687/Project website: http://www.scc.lancs.ac.uk/research/projects/DBS/
DOI: 10.6084/m9.figshare.5531866
title: Supplementary Material for: Low-Dose Allergen-Specific Immunotherapy Induces Tolerance in a Murine Model of Shrimp Allergy

description: <b><i>Background:</i></b> The efficacy and safety of allergen-specific immunotherapy (AIT) are highly dose-dependent. <b><i>Methods:</i></b> We investigated the dosage effects of AIT and the underlying mechanisms in a murine model of shrimp hypersensitivity. BALB/c mice were sensitized with recombinant shrimp allergen rMet e 1 and challenged orally with a high dose of rMet e 1 to elicit an allergic response. These sensitized mice were then treated with a low (0.01 mg), medium (0.05 mg), or high dosage (0.1 mg) of rMet e 1 intraperitoneally before receiving a second oral challenge. The allergic responses and immunological changes in the gut were compared between animals receiving different dosages. <b><i>Results:</i></b> We found that all sensitized mice that received rMet e 1 immunotherapy were desensitized, regardless of the dosage, and protected at the second oral challenge. Nevertheless, the mice in the high-dosage group experienced severe systemic reactions during the treatment phase. In contrast, regulatory T (T<sub>reg</sub>) cell-associated genes were upregulated only in the low- and medium-dosage groups, and Foxp3+ cells were more abundant in the gut lymphoid tissues than in the high-dosage group. <b><i>Conclusions:</i></b> Our results demonstrate that low-dosage immunotherapy favors the induction of local Foxp3+ T<sub>reg</sub> cells and the upregulation of regulatory cytokines. The safety advantages and long-term efficacy of low-dosage immunotherapy should be taken into consideration when developing immunotherapy dose schedules.
DOI: 10.6084/m9.figshare.5531863
title: Raw data for the study "Effects of latent toxoplasmosis and Rh factor on olfactory functions of men and women"

description: For data description see the paper: Effects of latent toxoplasmosis and Rh factor on olfactory functions of men and women<br>AbstractThe prevalence of infection with <i>Toxoplasma</i> is much higher in schizophrenia patients than in the general population. It is known that this parasite, which infects about one third of the world population, induces specific behavioral and personality changes in its animal and human hosts. It has been suggested that certain symptoms of schizophrenia, including changes in olfactory functions, are in fact symptoms of latent toxoplasmosis that can be easily detected in schizophrenia patients only due to the increased prevalence of toxoplasmosis in this population. Schizophrenia patients have impaired identification of odors and probably have lower sensitivity of odor detection. Here we searched for differences in olfactory functions between 62 infected and 61 noninfected non-schizophrenic subjects. When the potential confounding variables were controlled, infected men scored better in the standard odor-identification test. The <i>Toxoplasma</i>-infected women rated all smells as more intensive while the <i>Toxoplasma</i>-infected men rated nearly all smells as less intensive. Infected women rated the pleasantness of the smell of undiluted cat urine as higher than the non-infected women and the opposite was true for the men (the opposite direction shifts in men and women were described earlier for highly diluted cat urine). Toxoplasmosis had no effect on the rated pleasantness of the smell of jasmin, moschus, ambra, and zibet. Our results suggest that latent toxoplasmosis is associated with changes in the olfactory functions in humans; however, the observed changes qualitatively differ from those characteristic observed in schizophrenia patients.
DOI: 10.6084/m9.figshare.5531863.v1
title: Raw data for the study "Effects of latent toxoplasmosis and Rh factor on olfactory functions of men and women"

description: For data description see the paper: Effects of latent toxoplasmosis and Rh factor on olfactory functions of men and women<br>AbstractThe prevalence of infection with <i>Toxoplasma</i> is much higher in schizophrenia patients than in the general population. It is known that this parasite, which infects about one third of the world population, induces specific behavioral and personality changes in its animal and human hosts. It has been suggested that certain symptoms of schizophrenia, including changes in olfactory functions, are in fact symptoms of latent toxoplasmosis that can be easily detected in schizophrenia patients only due to the increased prevalence of toxoplasmosis in this population. Schizophrenia patients have impaired identification of odors and probably have lower sensitivity of odor detection. Here we searched for differences in olfactory functions between 62 infected and 61 noninfected non-schizophrenic subjects. When the potential confounding variables were controlled, infected men scored better in the standard odor-identification test. The <i>Toxoplasma</i>-infected women rated all smells as more intensive while the <i>Toxoplasma</i>-infected men rated nearly all smells as less intensive. Infected women rated the pleasantness of the smell of undiluted cat urine as higher than the non-infected women and the opposite was true for the men (the opposite direction shifts in men and women were described earlier for highly diluted cat urine). Toxoplasmosis had no effect on the rated pleasantness of the smell of jasmin, moschus, ambra, and zibet. Our results suggest that latent toxoplasmosis is associated with changes in the olfactory functions in humans; however, the observed changes qualitatively differ from those characteristic observed in schizophrenia patients.
DOI: 10.6084/m9.figshare.5531866.v1
title: Supplementary Material for: Low-Dose Allergen-Specific Immunotherapy Induces Tolerance in a Murine Model of Shrimp Allergy

description: <b><i>Background:</i></b> The efficacy and safety of allergen-specific immunotherapy (AIT) are highly dose-dependent. <b><i>Methods:</i></b> We investigated the dosage effects of AIT and the underlying mechanisms in a murine model of shrimp hypersensitivity. BALB/c mice were sensitized with recombinant shrimp allergen rMet e 1 and challenged orally with a high dose of rMet e 1 to elicit an allergic response. These sensitized mice were then treated with a low (0.01 mg), medium (0.05 mg), or high dosage (0.1 mg) of rMet e 1 intraperitoneally before receiving a second oral challenge. The allergic responses and immunological changes in the gut were compared between animals receiving different dosages. <b><i>Results:</i></b> We found that all sensitized mice that received rMet e 1 immunotherapy were desensitized, regardless of the dosage, and protected at the second oral challenge. Nevertheless, the mice in the high-dosage group experienced severe systemic reactions during the treatment phase. In contrast, regulatory T (T<sub>reg</sub>) cell-associated genes were upregulated only in the low- and medium-dosage groups, and Foxp3+ cells were more abundant in the gut lymphoid tissues than in the high-dosage group. <b><i>Conclusions:</i></b> Our results demonstrate that low-dosage immunotherapy favors the induction of local Foxp3+ T<sub>reg</sub> cells and the upregulation of regulatory cytokines. The safety advantages and long-term efficacy of low-dosage immunotherapy should be taken into consideration when developing immunotherapy dose schedules.
DOI: 10.6084/m9.figshare.5531839
title: Supplementary Material for: Nasonia Parasitic Wasps Escape from Haller's Rule by Diphasic, Partially Isometric Brain-Body Size Scaling and Selective Neuropil Adaptations

description: Haller's rule states that brains scale allometrically with body size in all animals, meaning that relative brain size increases with decreasing body size. This rule applies both on inter- and intraspecific comparisons. Only 1 species, the extremely small parasitic wasp <i>Trichogramma evanescens</i>, is known as an exception and shows an isometric brain-body size relation in an intraspecific comparison between differently sized individuals. Here, we investigated if such an isometric brain-body size relationship also occurs in an intraspecific comparison with a slightly larger parasitic wasp, <i>Nasonia vitripennis</i>, a species that may vary 10-fold in body weight upon differences in levels of scramble competition during larval development. We show that <i>Nasonia</i> exhibits diphasic brain-body size scaling: larger wasps scale allometrically, following Haller's rule, whereas the smallest wasps show isometric scaling. Brains of smaller wasps are, therefore, smaller than expected and we hypothesized that this may lead to adaptations in brain architecture. Volumetric analysis of neuropil composition revealed that wasps of different sizes differed in relative volume of multiple neuropils. The optic lobes and mushroom bodies in particular were smaller in the smallest wasps. Furthermore, smaller brains had a relatively smaller total neuropil volume and larger cellular rind than large brains. These changes in relative brain size and brain architecture suggest that the energetic constraints on brain tissue outweigh specific cognitive requirements in small <i>Nasonia</i> wasps.
DOI: 10.6084/m9.figshare.5531839.v1
title: Supplementary Material for: Nasonia Parasitic Wasps Escape from Haller's Rule by Diphasic, Partially Isometric Brain-Body Size Scaling and Selective Neuropil Adaptations

description: Haller's rule states that brains scale allometrically with body size in all animals, meaning that relative brain size increases with decreasing body size. This rule applies both on inter- and intraspecific comparisons. Only 1 species, the extremely small parasitic wasp <i>Trichogramma evanescens</i>, is known as an exception and shows an isometric brain-body size relation in an intraspecific comparison between differently sized individuals. Here, we investigated if such an isometric brain-body size relationship also occurs in an intraspecific comparison with a slightly larger parasitic wasp, <i>Nasonia vitripennis</i>, a species that may vary 10-fold in body weight upon differences in levels of scramble competition during larval development. We show that <i>Nasonia</i> exhibits diphasic brain-body size scaling: larger wasps scale allometrically, following Haller's rule, whereas the smallest wasps show isometric scaling. Brains of smaller wasps are, therefore, smaller than expected and we hypothesized that this may lead to adaptations in brain architecture. Volumetric analysis of neuropil composition revealed that wasps of different sizes differed in relative volume of multiple neuropils. The optic lobes and mushroom bodies in particular were smaller in the smallest wasps. Furthermore, smaller brains had a relatively smaller total neuropil volume and larger cellular rind than large brains. These changes in relative brain size and brain architecture suggest that the energetic constraints on brain tissue outweigh specific cognitive requirements in small <i>Nasonia</i> wasps.
DOI: 10.6084/m9.figshare.5531788
title: Raw data file from Kleptopredation: a mechanism to facilitate planktivory in a benthic mollusc

description: All raw data from behavioural assays and stable isotope analyses
DOI: 10.6084/m9.figshare.5531788.v1
title: Raw data file from Kleptopredation: a mechanism to facilitate planktivory in a benthic mollusc

description: All raw data from behavioural assays and stable isotope analyses
DOI: 10.6084/m9.figshare.5531770
title: Internal representation of hippocampal neuronal population span a time-distance continuum

description: Calcium imaging data (GCamp6f) in the pyramidal cell layer of hippocampal region CA1 of a mouse running on a nonmotorized uncued treadmill.200s samples of 1400s imaging sessions performed on the same mouse on two consecutive days.Resolution : 200x200pxFrequency : 10HzField-of-view : 400x400µm
DOI: 10.6084/m9.figshare.5531749
title: Supplementary Material for: Positron Emission Tomography (PET) and PET/CT in Thyroid Cancer: A Systematic Review and Meta-Analysis

description: <b><i>Background:</i></b> Positron emission tomography (PET) and PET/CT are functional imaging methods that are widely used in diagnostic procedures in oncology. <b><i>Objectives:</i></b> The objective of this study was to assess the patient-relevant benefit of PET or PET/CT in patients with thyroid cancer based on a literature review and meta-analysis. <b><i>Methods:</i></b> A systematic review including studies that had been published until December 2013 was performed. To be included, studies had to prospectively investigate patients with thyroid cancer in a clinical setting of staging, restaging, or diagnosing tumour recurrence. <b><i>Results:</i></b> Out of 3,506 potentially relevant articles, 29 studies were included. No study directly evaluated the benefits of PET. Twenty-eight studies dealt with the diagnostic accuracy of PET or PET/CT, and 1 study evaluated the prognostic value of PET/CT. The authors showed that a positive result of PET/CT in restaging patients with differentiated thyroid cancer yielded a significant decrease in overall survival (hazard ratio, HR 5.01, CI 3.41–6.62). In patients with suspected recurrence of differentiated thyroid cancer, meta-analysis showed higher sensitivity of PET (89.7%, CI 78–99%) and PET/CT (94.3%, CI 87–97%) compared with conventional imaging (65.4%, CI 32–88%) and comparable results for specificity. Due to the low numbers of studies and patients, meta-analyses on medullary carcinoma did not produce meaningful results. <b><i>Conclusion:</i></b> The patient-relevant benefits of PET or PET/CT in thyroid cancer could not be evaluated satisfactorily based on the included studies. It remains unclear whether higher diagnostic test accuracy leads to changes in therapeutic strategies and better patient-relevant outcomes.
DOI: 10.6084/m9.figshare.5531755
title: Supplementary Material for: Bevacizumab in Combination with Platinum-Based Chemotherapy in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with or without Brain Metastases: A French Cohort Study (EOLE)

description: <b><i>Objectives:</i></b> The aim of this study was to describe the characteristics of patients receiving bevacizumab plus first-line metastatic chemotherapy for non-squamous advanced non-small cell lung cancer (aNSCLC), with or without brain metastases, in routine clinical practice. Other objectives were to describe treatment efficacy, modalities of use, and safety. <b><i>Methods:</i></b> For this non-interventional, prospective, national, multicentre study, data were collected every 3 months over 18 months. <b><i>Results:</i></b> Of the 407 patients analysed, 84 (21%) with brain metastases at bevacizumab initiation had poorer general health than patients with no brain metastases (Eastern Cooperative Oncology Group [ECOG] performance status score = 2: 16 vs. 11%). All but 2 patients received bevacizumab (7.5 or 15 mg/kg/3 weeks in 99% of patients) in combination with doublet chemotherapy. Median progression-free survival and overall survival did not differ significantly between patients with or without brain metastases (6.5 months, 95% CI 5.7-8.1 vs. 6.9 months, 95% CI 5.9-7.6, <i>p</i> = 0.57; 14.5 months, 95% CI 10.0 vs. 12.5 months, 95% CI 10.1-14.7, <i>p</i> = 0.33). In 30 and 32% of the patients, respectively, at least one serious adverse event was reported, with a causal relationship to bevacizumab in 20 and 21% of the patients. <b><i>Conclusion:</i></b> This study confirmed in a real-life setting the safety profile and survival benefits of first-line chemotherapy with bevacizumab in aNSCLC patients with brain metastases.
DOI: 10.6084/m9.figshare.5531755.v1
title: Supplementary Material for: Bevacizumab in Combination with Platinum-Based Chemotherapy in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with or without Brain Metastases: A French Cohort Study (EOLE)

description: <b><i>Objectives:</i></b> The aim of this study was to describe the characteristics of patients receiving bevacizumab plus first-line metastatic chemotherapy for non-squamous advanced non-small cell lung cancer (aNSCLC), with or without brain metastases, in routine clinical practice. Other objectives were to describe treatment efficacy, modalities of use, and safety. <b><i>Methods:</i></b> For this non-interventional, prospective, national, multicentre study, data were collected every 3 months over 18 months. <b><i>Results:</i></b> Of the 407 patients analysed, 84 (21%) with brain metastases at bevacizumab initiation had poorer general health than patients with no brain metastases (Eastern Cooperative Oncology Group [ECOG] performance status score = 2: 16 vs. 11%). All but 2 patients received bevacizumab (7.5 or 15 mg/kg/3 weeks in 99% of patients) in combination with doublet chemotherapy. Median progression-free survival and overall survival did not differ significantly between patients with or without brain metastases (6.5 months, 95% CI 5.7-8.1 vs. 6.9 months, 95% CI 5.9-7.6, <i>p</i> = 0.57; 14.5 months, 95% CI 10.0 vs. 12.5 months, 95% CI 10.1-14.7, <i>p</i> = 0.33). In 30 and 32% of the patients, respectively, at least one serious adverse event was reported, with a causal relationship to bevacizumab in 20 and 21% of the patients. <b><i>Conclusion:</i></b> This study confirmed in a real-life setting the safety profile and survival benefits of first-line chemotherapy with bevacizumab in aNSCLC patients with brain metastases.
DOI: 10.6084/m9.figshare.5531692
title: Fungal genome assemblies and gene sets from metagenomic lichen thalli

description: Fungal genome assemblies and gene sets from metagenomic lichen thalli of two species assembled with SPAdes. Taxonomic assignment of metagenomic reads to Ascomycota was performed with MEGAN and MetaWatt.<br>
DOI: 10.6084/m9.figshare.5531686

description: This video is a first draft for the proposed submission to film festivals, specifically craft film orientated. The most important thing to bear in mind is that this construction is for a specific audience and for a specific purpose; marketing and promotion of the museum and validation of the arts council funding. Other constructions are now possible from the component parts of this video and other components already sorted and archived. <br>
DOI: 10.6084/m9.figshare.5531698
title: Dataset for: Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients

description: Mutations and splice variants in the estrogen receptor (ER) gene, ESR1, may yield endocrine resistance in metastatic breast cancer (MBC) patients. These putative endocrine resistance markers are likely to emerge during treatment and therefore its detection in liquid biopsies, such as circulating tumor cells (CTCs) and cell-free DNA (cfDNA), is of great interest. This research aimed to determine if ESR1 mutations and splice variants occur more frequently in CTCs of MBC patients progressing on endocrine treatment. In addition, the presence of ESR1 mutations was evaluated in matched cfDNA and compared to CTCs. CellSearch-enriched CTC fractions (≥5/7.5 mL) of two MBC cohorts were evaluated, including 1) patients starting first-line endocrine therapy (n=43, baseline cohort) and 2) patients progressing on any line of endocrine therapy (n=40, progressing cohort). ESR1 hotspot mutations (D538G and Y537S/N/C) were evaluated in CTC-enriched DNA using digital PCR and compared with matched cfDNA (n=18 baseline cohort; n=26 progressing cohort). Expression of ESR1 full-length and 4 of its splice variants (∆5, ∆7, 36KD and 46KD) was evaluated in CTC-enriched mRNA. It was observed that in the CTCs, the ESR1 mutations were not enriched in the progressing cohort (8%), when compared to the baseline cohort (5%) (P=0.66). In the cfDNA, however, ESR1 mutations were more prevalent in the progressing cohort (42%) than in the baseline cohort (11%) (P=0.04). Three of the same mutations were observed in both CTCs and cfDNA, 1 mutation in CTCs only and 11 in cfDNA only. Only the ∆5 ESR1 splice variant was CTC-specific expressed, but was not enriched in the progressing cohort. In conclusion, sensitivity for detecting ESR1 mutations in CTC-enriched fractions was lower than for cfDNA. ESR1 mutations detected in cfDNA, rarely present at start of first-line endocrine therapy, were enriched at progression, strongly suggesting a role in conferring endocrine resistance in MBC.